publication date: Oct. 20, 2016

NCI CTEP-Approved Trials for the Month of October

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase I 9950

A phaseI Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma

(HNSCC; SDC 10060121)

JHU Sidney Kimmel Comprehensive

Cancer Center LAO

Owonikoko, Taofeek Kunle

(404) 778-5575


Phase II NRG-GY008

A phaseII Evaluation of Copanlisib (BAY 80-6946) (IND #130822), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations

NRG Oncology

Santin, Alessandro D.

(203) 785-6301


Phase II A011502

A Randomized phaseIII Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer

The ABC Trial Alliance for Clinical Trials in Oncology Chen, Wendy Yvonne

(617) 632-3800


Phase Other AOST16B1-Q

An Integrated Clinical and Genomic Analysis of Treatment Failure in Pediatric Osteosarcoma

Children’s Oncology Group

Onel, Kenan

(773) 702-4919

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.